CAS Insight

molecules of the month

Arvinas ER Chimeric Degrader

CRBN-based heterobifunctional ER degrader

oral Ph. II candidate for ER+/HER2- BC

from ER ligand and CRBN ligand


Arvinas, New Haven, CT

Arvinas ARV-471 ER Degrader
2 mins read

The Arvinas ER chimeric degrader, ARV-471, is an oral, bioavailable ER degrading CRBN-based  PROTAC for the treatment of patients with ER+/HER2- breast cancer. Along with ARV-110, it is one of the first chimeric degraders to enter a Ph. II clinical trial. It was first disclosed at AACR in early 2021, and though the molecules have not been formally published yet, related analogs have been published and characterized. ER degradation with SERDs like fulvestrant is a well-validated mechanism, but fulvestrant doesn’t appear to achieve complete degradation of ER. ARV-471 achieves deeper tumor regression in preclinical models over fulvestrant, at much lower doses, and has a more prominent effect in combination with CDK4/6 inhibitor palbociclib. In humans, the molecule has an effective…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: